Patients in a phase 3 clinical trial taking Lilly’s orforglipron, an investigational oral GLP-1 receptor agonist, lost an average of 10.5%, or 22.9 pounds, with an A1C that was reduced by 1.8%, the company announced today.

“Based on my experience leading clinical trials in obesity and diabetes, these data show the potential for orforglipron to offer an efficacy, safety, and tolerability profile consistent with the injectable GLP-1 class,” Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, said in a news release . “Orforglipron could help health care providers expand treatment options for patients who prefer oral therapies without compromising clinical results.”

In the ATTAIN-2 trial, orforglipron met the primary endpoint of weight

See Full Page